Foamix Pharmaceuticals Ltd.
CIK 0001606645
Revenue (TTM)
$3.04M
−56.2% YoY
FY Mar 2020
Net Income (TTM)
−$72.84M
−28.3% YoY
FY Mar 2020
EPS Diluted (TTM)
—
FY Mar 2020
Gross Margin
108.2%
FY Mar 2020
Operating Margin
-2,432.7%
FY Mar 2020
Net Margin
-2,393.6%
FY Mar 2020
Free Cash Flow (TTM)
−$74.45M
FY Mar 2020
Cash
$43.76M
FY Mar 2020
Total Debt
$33.2M
FY Mar 2020
Shares Outstanding
61.63M sh
FY Mar 2020